PRKCG Antibodies

Protein kinase C gamma type (PRKCG)

Calcium-activated, phospholipid- and diacylglycerol (DAG)-reliant serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye cells, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of adrenal and adrenal functions related to sensitivity to opiates, alcohol and pain, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by raising plasma membrane-associated GRIA4 expression.

May be involved in the regulation of hippocampal long-term potentiation (LTP), but might be not essential for the practice of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and might be crucial for the development and/or maintenance of morphine-induced reinforcing consequences in the limbic forebrain.

Gene Information

Human
Gene Name:	PRKCG
Uniprot:	P05129
Entrez:	5582

Family

Belongs to:
protein kinase superfamily

Alternative Names

EC 2.7.11; EC 2.7.11.13; MGC57564; PKC gamma; PKCC; PKCCSCA14; PKCG; PKC-gamma; PKCGprotein kinase C gamma type; PRKCG; protein kinase C, gamma; SCA14

Molecular Weight

Mass (kDA):
78.448 kDA

Genomic Context

Human
Location:	19q13.42
Sequence:	19; NC_000019.10 (53882197..53907652)

Tissue Specificity

Expressed in Purkinje cells of the cerebellar cortex.

Subcellular Localizations

Cytoplasm. Cytoplasm, perinuclear region. Cell membrane; Peripheral membrane protein. Cell junction, synapse, synaptosome. Cell projection, dendrite. Translocates to synaptic membranes on stimulation.

Diseases

• Ataxia
• Ataxia, Spinocerebellar
• Cerebellar Ataxia
• Neurodegenerative Disorders
• Myoclonus
• Myotonic Dystrophy
• Atrophy
• Cerebellar Diseases
• Dystrophy
• Epilepsy
• Impaired Cognition
• Nerve Degeneration

• Gait Ataxia
• Dystonia Disorders
• Nervous System Disorder
• Retinitis Pigmentosa
• Spinocerebellar Degeneration
• Hereditary Ataxia, Unspecified

Pathways

• Pathogenesis
• Cell Adhesion
• Cell Proliferation
• Cell Cycle
• Synaptic Transmission

PTMs

• Phosphorylation

• Ubiquitination

Research Areas

• Protein Kinase
• Signal Transduction
• Wnt Signaling Pathway

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PRKCG

Best Uses Of The PRKCG Marker

Boster Bio offers a great solution if you are looking to purchase an antibody against the PRKCG protein. Boster's antibody has been tested on multiple platforms using positive and negative samples. Boster's antibody is highly specific and have high affinity. Boster rewards scientists who review their products and reward them for being the first users. This gives scientists across the world the opportunity to review their product and earn product credits.

Boster Bio Anti-PKC Gamma/PRKCG antibody

This rabbit polyclonal PKC gamma/PRKCG antibody is now available for purchase via the Picoband(tm) catalog. The antibody has been tested for activity in IHC/ICC/IF. This antibody is compatible with Rat, Mouse, and Human samples. Antibodies are stored at -20 degrees C until they are used. Avoid freezing-thawing cycles to ensure that the antibody is in the proper amount before use.

Boster anti-PKC Gamma/PRKCCG antibodies recognize PKC Gamma in mouse brain tissues and formalin-fixed human brain tissue. The secondary antibody was peroxidase-conjugated and used for signal visualization by chemiluminescence. The clinical efficacy of the anti-PKC Gamma antibody has not been determined.

Boster Bio: Immunofluorescence

The PRKCG marker is an epitope of the PKC Gamma gene, which can be found in the cell membrane. This protein is essential for the production of a variety of hormones and proteins, including insulin. The highest expression is in the brain, which is a good indicator for various cancers. In addition to being used in biopsies of tumors PRKCG gene also has other uses.

Immunofluorescence

The PRKCG gene is a peptide specific to tumors that is present in about 40 percent of all human cancers. It is expressed in the tumor and doesn't exhibit the negative effects of central tolerance. Its tumor-specificity as well as its small size make it ideal for the development of new drugs. Its size is small, which allows it to concentrate on the mutational area of the protein without the need for huge molecules, which could lead to unrelated antigenic competition.

ICC

The PRKCG Marker is a protein which regulates a variety of biological processes. The enzyme is activated by diacylglycerol, which attaches to the C1 domain. The agonist releases a pseudo-inhibitory substance that is located in the catalytic domain. The enzyme then phosphorylates target substrates. This protein is found in all tissues in our bodies.

IHC

IHC and the PRKCG marker play different roles in the detection of cancer. In some cancers, high levels of PRKCB are associated with a greater survival time compared to low levels. These two genes are linked to certain types of cancer. BRCA patients with high PRKCB levels are more likely to survive than LGG patients with LUAD, SKCM, and LUAD tumors. Patients with low PRKCCG have a worse prognosis.

The PRKCG antibody can be described as a polyclonal antibody that detects endogenous levels of human PRKCG protein. It is affinity-purified from rabbit antiserum and is derived from an epitope-specific immunegen. This antibody detects endogenous levels of PRKCG protein and recognizes a nonphosphopeptide, which is derived from the human protein. The PRKCG antibody can be used as a monoclonal antibody, or conjugated with the FITC.

Higher levels of PRKCI were associated with a lower response to immunotherapies in other cancers. This effect was not restricted to LGG. PRKCI and PRKCD were also associated with higher expression of PD-1 in the immune system. Both of these markers are vital in the diagnosis of cancer and treatment, and are a good indicator of the type of cancer a patient has.

The molecular characterization of PRKCG gene is not easy. There are many private, conventional mutations in this gene. The phenotypic phenotypes associated with the gene are not specific. A multicenter study of patients suffering from SCA/PRKCG involved both prospective neuropsychological and standardized 3D MR Imaging. Protein modeling was also employed to classify variants that were not clear of significance.